Pain – Opioids

  • Opana 2016 report

    Opana 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Oxaydo 2016 report

    Oxaydo 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • OxyContin 2016 report

    OxyContin 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Subsys 2016 report

    Subsys 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Zohydro ER 2016 report

    Zohydro ER 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this...

  • Abstral 2015 report

    Abstral 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 35 Pages The 5 Key Questions Addressed by this...

  • Butrans 2015 report

    Butrans 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 29 Pages The 5 Key Questions Addressed by this...

  • Embeda 2015 report

    Embeda 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Fentora 2015 report

    Fentora 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 33 Pages The 5 Key Questions Addressed by this...

  • Hysingla ER 2015 report

    Hysingla ER 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 29 Pages The 5 Key Questions Addressed by...

  • Ionsys 2015 report

    Ionsys 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 29 Pages The 5 Key Questions Addressed by this...

  • Lazanda 2015 report

    Lazanda 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 33 Pages The 5 Key Questions Addressed by this...